Scarica l'app Stockscreener
0.7856
3.01%
-0.0244
Dopo l'orario di chiusura:
2.58
1.7944
+228.41%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.81
Aprire:
$0.7966
Volume 24 ore:
125.21K
Relative Volume:
0.67
Capitalizzazione di mercato:
$8.43M
Reddito:
-
Utile/perdita netta:
$-3.28M
Rapporto P/E:
-0.7549
EPS:
-1.0406
Flusso di cassa netto:
$-4.80M
1 W Prestazione:
+7.32%
1M Prestazione:
+8.76%
6M Prestazione:
-4.61%
1 anno Prestazione:
-25.18%
Intervallo 1D:
$0.7702
$0.8105
Intervallo di 1 settimana:
$0.6999
$0.8579
Portata 52W:
$0.63
$1.51
Pharmacyte Biotech Inc Stock (PMCB) Company Profile
Nome
Pharmacyte Biotech Inc
Settore
Industria
Telefono
(917) 595.2850
Indirizzo
3960 HOWARD HUGHES PARKWAY, LAS VEGAS
Compare PMCB vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 2.24 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.40 | 2.93B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
7.50 | 432.93M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.13 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.29 | 288.61M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.54 | 0 | 0 | 0 | 0 | 0.00 |
Pharmacyte Biotech Inc Borsa (PMCB) Ultime notizie
PharmaCyte Biotech (PMCB) Edges Higher: Support-Holding Action at $0.81Long Setup Ideas - Newser
PMCB Q1 2026 Earnings: Pre-Revenue Biotech Reports Negative EPS; Stock Rises on Potential Pipeline Progress - Newser
PharmaCyte Biotech Inc. (PMCB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PharmaCyte Biotech (PMCB) Rallies 5.6% as Biotech Sentiment ImprovesNHNL Divergence - Newser
PharmaCyte Biotech (PMCB) Q1 2026 Earnings: Narrowing Loss Amid Strategic Pipeline ProgressHigh Estimate Range - Newser
PharmaCyte Biotech Inc. (PMCB) Q1 2026 Earnings: Pre-Revenue Biotech Reports Wider Loss Amid Strategic Pipeline ProgressShared Momentum Picks - Newser
PharmaCyte Biotech (PMCB) Q1 2026 Earnings: Revenue $N/A, Matching ViewsGuidance Revision Trend - Newser
TradingKey - TradingKey
PharmaCyte Biotech (PMCB) Stock: Buy or Sell |Risk Report - newser.com
PMCB SEC FilingsPharmacyte Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
PMCB Stock Jumps 25% After Company Sells Stake In Femasys - MSN
PharmaCyte Biotech (PMCB) Stock Take Profit (Gains) 2026-04-20Trending Social Stocks - Newser
Aug Intraday: Is PharmaCyte Biotech Inc a good ESG investment2026 Short Interest & Accurate Trade Setup Notifications - baoquankhu1.vn
PharmaCyte Biotech Operating Margin | PMCB - MLQ.ai
EV Market: Should I invest in PharmaCyte Biotech Inc before earningsJobs Report & Weekly High Return Opportunities - baoquankhu1.vn
How liquid is PharmaCyte Biotech Inc stockPortfolio Performance Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Is PharmaCyte Biotech (PMCB) Stock Near Support | Price at $0.69, Up 5.96%Combination Correction - Newser
Aug Ideas: What is the Moat Score of PharmaCyte Biotech Inc2026 EndofYear Setup & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Is PharmaCyte Biotech Inc vulnerable to short sellersMarket Sentiment Report & Growth Focused Stock Pick Reports - baoquankhu1.vn
PharmaCyte Biotech Shareholders Approve Governance and Equity Actions - The Globe and Mail
Director Weinstein receives 119,170 stock options at PharmaCyte Biotech (PMCB) - Stock Titan
Director at PharmaCyte Biotech (PMCB) gets 119,170 options - Stock Titan
PharmaCyte Biotech (PMCB) director awarded 119,170 stock options at $0.67 - Stock Titan
PharmaCyte Biotech (PMCB) director receives 119,170 stock options at $0.67 - Stock Titan
PharmaCyte Biotech (PMCB) wins approval for reverse split range and 2M new plan shares - Stock Titan
PMCB Stock Chart | PHARMACYTE BIOTECH INC (NASDAQ:PMCB) - ChartMill
Insider Sell: How liquid is PharmaCyte Biotech Inc stock2026 Setups & Safe Entry Momentum Tips - baoquankhu1.vn
PharmaCyte Biotech, Inc. (PMCB) Q3 2026 10-Q Report: Financial Results, Stock Information, and SEC Filings - Minichart
PharmaCyte Biotech (PMCB) logs neutral Form 4 as 10% FEMASYS (FEMY) owner - Stock Titan
PharmaCyte Biotech (FEMY) reports 7.87% stake including warrants - Stock Titan
PharmaCyte Biotech 10-Q: $0.0M Revenue, $(0.17) EPS (Q3), $(2.41) EPS (YTD) - TradingView
PharmaCyte Biotech (NASDAQ: PMCB) details Jan 2026 results and cash runway - Stock Titan
PharmaCyte Biotech delays quarterly report filing - MSN
Analyzing Prime Medicine (NYSE:PRME) & PharmaCyte Biotech (OTCMKTS:PMCBD) - Defense World
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
PharmaCyte Biotech (PMCB) seeks reverse split, equity plan boost at 2026 meeting - Stock Titan
Aug Catalysts: Can PharmaCyte Biotech Inc. stock weather global recessionWeekly Profit Summary & Safe Capital Growth Plans - Naître et grandir
PMCB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Technical Analysis - Intellectia AI
PharmaCyte Biotech (PMCB) seeks reverse split and 2M share plan boost at virtual meeting - Stock Titan
Day Trade: Can PharmaCyte Biotech Inc keep up with sector leadersJuly 2025 Trends & Free Long-Term Investment Growth Plans - baoquankhu1.vn
PharmaCyte Biotech (OTCMKTS:PMCBD) Trading 5.9% Higher – Time to Buy? - Defense World
Volume Summary: What is SIM Acquisition Corp Is P E ratio telling usJuly 2025 Catalysts & Trade Opportunity Analysis Reports - baoquankhu1.vn
Dow Update: Is PharmaCyte Biotech Inc vulnerable to short sellersMarket Risk Summary & Verified Trade Idea Suggestions - baoquankhu1.vn
Is PharmaCyte Biotech Inc. trading at a discountWeekly Stock Report & Weekly High Momentum Picks - mfd.ru
Pharmacyte Biotech Inc Azioni (PMCB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):